34127-96-3

Basic information

• Product Name: 3-BUTOXY-4-METHOXYBENZALDEHYDE
• Synonyms: 3-Butoxy-4-methoxybenzaldehyde
• CAS NO: 34127-96-3
• Molecular Formula: C₁₂H₁₆O₃
• Molecular Weight: 208.25
• Mol File: 34127-96-3.mol

Chemical Properties

• Boiling Point: 319.9°C at 760 mmHg
• Flash Point: 138.3°C
• Appearance: /
• Density: 1.048g/cm³
• Vapor Pressure: 0.00033mmHg at 25°C
• Refractive Index: 1.518
• CAS DataBase Reference: 3-BUTOXY-4-METHOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BUTOXY-4-METHOXYBENZALDEHYDE(34127-96-3)
• EPA Substance Registry System: 3-BUTOXY-4-METHOXYBENZALDEHYDE(34127-96-3)

Safety Data

• Hazardous Substances Data: 34127-96-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H16O3/c1-3-4-7-15-12-8-10(9-13)5-6-11(12)14-2/h5-6,8-9H,3-4,7H2,1-2H3

Upstream product

• 51241-33-9 1-n-butoxy-2-methoxybenzene 
• 93-61-8 N-methyl-N-phenylformamide 
• 90-05-1 2-methoxy-phenol 
• 621-59-0 isovanillin 
• 542-69-8 1-iodo-butane 
• 109-65-9 1-bromo-butane 

Downstream Products

• 51301-93-0 2-Phenyl-4-(4-methoxy-3-n-butoxybenzal)-5-oxo-oxazolin 
• 621-59-0 isovanillin 
• 161179-23-3 C₁₂H₁₈O₃ 
• 85258-95-3 5-(3-Butoxy-4-methoxy-phenyl)-thiazolidine-2,4-dione 
• 139488-45-2 3-(n-butoxy)-4-methoxybenzoyl chloride 
• 66924-20-7 acide 3-n-butoxy-4-methoxybenzoique 

Relevant articles and documents

Understanding the cytotoxic effects of new isovanillin derivatives through phospholipid Langmuir monolayers

Twenty-one isovanillin derivatives were prepared in order to evaluate their cytotoxic properties against the cancer cell lines B16F10-Nex2, HL-60, MCF-7, A2058 and HeLa. Among them, seven derivatives exhibited cytotoxic activity. We observed that for obtaining smaller IC50 values and for increasing the index of selectivity, two structural features are very important when compared with isovanillin (1); a hydroxymethyl group at C-1 and the replacement of the hydroxyl group at C-3 by different alkyl groups. As the lipophilicity of the compounds was changed, we decided to investigate the interaction of the cytotoxic isovallinin derivatives on cell membrane models through Langmuir monolayers by employing the lipids DPPC (1,2-diplamitoyl-sn-glycero-3-phosphocoline) and DPPS (1,2-diplamitoyl-sn-glycero-3-phosphoserine). The structural changes on the scaffold of the compounds modulated the interaction with the phospholipids at the air-water interface. These results were very important to understand the biophysical aspects related to the interaction of the cytotoxic compounds with the cancer cell membranes.

Concurrent synthesis of vanillin and isovanillin

A method for concurrent synthesis of vanillin and isovanillin has been developed by a nonregioselective Vilsmeier-Haack reaction of O-alkyl guaiacols. O-Alkylation of guaiacol provided the corresponding O-alkyl guaiacol (1), which was then formylated with N-methylformanilide/phosphorus oxychloride to give a mixture of 4-alkoxy-3-methoxy-benzaldehyde (2) and 3-alkoxy-4- methoxybenzaldehyde (3). Finally, the obtained mixture underwent a selective dealkylation by anhydrous aluminium trichloride, while leaving methyl groups intact to simultaneously achieve the significant fine chemicals vanillin and isovanillin.

Discovery and structural modification of 1-phenyl-3-(1-phenylethyl)urea derivatives as inhibitors of complement

A series of 1-phenyl-3-(1-phenylethyl)urea derivatives were identified as novel and potent complement inhibitors through structural modification of the original compound from high-throughput screening. Various analogues (7 and 13-15) were synthesized and identified as complement inhibitors, with the introduction of a five- or six-carbon chain (7c, 7d, 7k, 7l, and 7o) greatly improving their activity. Optimized compound 7l has an excellent inhibition activity with IC50 values as low as 13 nM. We demonstrated that the compound 7l inhibited C9 deposition through the classical, the lectin, and the alternative pathways but had no influence on C3 and C4 depositions.

PYRIMIDINE AND QUINAZOLINE DERIVATIVES

This invention is concerned with compounds of the formula ( l ) wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES

This invention is concerned with compounds of the formula wherein A, R1 to R5 are as defined in the specification and G is a pyridine, quinoline or pyrimidine group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

BENZOIMIDAZOLE, TETRAHYDRO-QUINOXALINE, BENZOTRIAZOLE, DIHYDRO-IMIDAZO[4,5-c] PYRIDINONE AND DIHYDRO-ISOINDOLONE DERIVATIVES

This invention relates to compounds of the formula wherein A, R1 to R3 are as defined in the specification and G is benzoimidazole, quinoxaline, benzotriazole, dihydro-imidazo[4,5-c]pyridine and dihydro-isoindolone group as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES

This invention relates to 4,4-disubstituted piperidine derivatives of the formula wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceuti

PHENYL, PYRIDINE, QUINOLINE, ISOQUINOLINE, NAPHTHYRIDINE AND PYRAZINE DERIVATIVES

This invention is concerned with compounds of the formulaand pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES

This invention relates to 4,4-disubstituted piperidine derivatives of the formula (I) wherein A and R1 to R5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmac

Pyrimidine, quinazoline, pteridine and triazine derivatives

This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.